Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International ConferenceBusiness Wire • 05/14/24
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire • 05/07/24
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other IndicationsBusiness Wire • 05/06/24
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory MedicineBusiness Wire • 05/03/24
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateBusiness Wire • 03/05/24
Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023Business Wire • 12/13/23
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of DirectorsBusiness Wire • 11/29/23
Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business UpdateBusiness Wire • 11/09/23
Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical AffairsBusiness Wire • 10/03/23
Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023Business Wire • 09/07/23
Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business UpdateBusiness Wire • 08/08/23
Gossamer Bio stock struggles from lack of near-term catalysts: analystsProactive Investors • 07/27/23
Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE ResultsBusiness Wire • 07/24/23
Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International ConferenceBusiness Wire • 05/18/23
Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business UpdateBusiness Wire • 05/09/23